STAT signaling in different breast cancer sub-types

Molecular and Cellular Endocrinology

Volumn 382, Issue 1, 2014, Pages 612-615

  Furth, Priscilla A ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b Dankook University   (South Korea)

Author keywords

Breast cancer sub types; ER+ breast cancer; HER2 amplified breast cancer; Signal Transducer and Activator of Transcription (STAT); Triple negative breast cancer

Indexed keywords

STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CLASSIFICATION; CANCER PROGNOSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; TREATMENT RESPONSE;

BREAST CANCER SUB-TYPES; ER; ER+ BREAST CANCER; ESTROGEN RECEPTOR; HER2; HER2 AMPLIFIED BREAST CANCER; HUMAN EPIDERMAL GROWTH FACTOR 2; IL; INTERLEUKIN; JAK; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PI3K; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT); STAT; TNBC; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84888305350     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.03.023     Document Type: Article

References (49)

1. Anon Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
2. Bertos N.R., Park M. Breast cancer - one term, many entities?. The Journal of Clinical Investigation 2011, 121:3789-3796.
3. Britschgi A., et al. JAK2/STAT 5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 2012, 22:796-811.
4. Chan S.R., et al. STAT 1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Research 2012, 14:R16.
5. Charpin C., et al. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. International Journal of Cancer. Journal international du cancer 2009, 124:2124-2134.
6. Chia S.K., et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clinical Cancer Research 2012, 18:4465-4472.
7. Choi J., et al. Differential expression of immune-related markers in breast cancer by molecular phenotypes. Breast Cancer Research and Treatment 2013, 137:417-429.
8. Clevenger C.V. Roles and regulation of stat family transcription factors in human breast cancer. The American Journal of Pathology 2004, 165:1449-1460.
9. Cotarla I., et al. STAT 5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. International Journal of Cancer 2004, 108:665-671.
10. Deng X.-S., et al. Metformin targets STAT 3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 2012, 11:367-376.
11. Diaz N., et al. Activation of STAT 3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clinical Cancer Research 2006, 12:20-28.
12. Dolled-Filhart M., et al. Tissue microarray analysis of signal transducers and activators of transcription 3 (STAT 3) and phospho-STAT 3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clinical Cancer Research 2003, 9:594-600.
13. Duru N., et al. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clinical Cancer Research 2012, 18:6634-6647.
14. Eroles P., et al. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treatment Teviews 2012, 38:698-707.
15. Geyer F.C., et al. Molecular classification of estrogen receptor-positive/luminal breast cancers. Advances in Anatomic Pathology 2012, 19:39-53.
16. Giordano C., et al. Leptin increases HER2 protein levels through a STAT 3-mediated up-regulation of Hsp90 in breast cancer cells. Molecular Oncology 2012, November 23. 10.1016/j.molonc.2012.11.002.
17. Godinho M.F.E., et al. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. British Journal of Cancer 2012, 107:947-955.
18. Gooch J.L., Christy B., Yee D. STAT 6 mediates interleukin-4 growth inhibition in human breast cancer cells. Neoplasia 2002, 4:324-331.
19. Greenwood C., et al. STAT 1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. Journal of Proteomics 2012, 75:3031-3040.
20. Guiu S., et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 working group statement. Annals of Oncology 2012, 23:2997-3006.
21. Han W., et al. STAT 1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT 3. Molecular Carcinogenesis 2012, June 12. 10.1002/mc.21936.
22. Jönsson G., et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Research 2010, 12:R42.
23. Kim Sun Young, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. International Journal of Oncology 2008, 32:89-95.
24. Kristensen V.N., et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:2802-2807.
25. Lee H.-J., et al. Oral administration of penta-O-galloyl-β-D-glucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT 3 inhibition. Carcinogenesis 2011, 32:804-811.
26. Lee H., et al. Acetylated STAT 3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:7765-7769.
27. Lehmann B.D., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of Clinical Investigation 2011, 121:2750-2767.
28. Lim E.J., et al. Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT 3 and STAT 5b pathways. PloS One 2012, 7:e33361.
29. Liu S., et al. The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells. The Journal of Biological Chemistry 2012, 287:30228-30239.
30. Lu S., et al. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. Modern Pathology 2013, 26:485-495.
31. Magkou C., et al. Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer. Histopathology 2012, 60:1125-1132.
32. Nevalainen M.T., et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. Journal of Clinical Oncology 2004, 22:2053-2060.
33. Park J.H., et al. Hwanggeumchal sorghum induces cell cycle arrest, and suppresses tumor growth and metastasis through Jak2/STAT pathways in breast cancer xenografts. PloS One 2012, 7:e40531.
34. Peck A.R., et al. Loss of nuclear localized and tyrosine phosphorylated STAT 5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. Journal of Clinical Oncology 2011, 29:2448-2458.
35. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Molecular Oncology 2011, 5:5-23.
36. Riggins R.B., et al. Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Research 2006, 66:7007-7015.
37. Rody A., et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Research 2011, 13:R97.
38. Ross J.S., et al. The HER-2 receptor and breast cancer: 10 years of targeted anti-HER-2 therapy and personalized medicine. The Oncologist 2009, 14:320-368.
39. Schaber J.D., et al. Prolactin activates STAT 1 but does not antagonize STAT 1 activation and growth inhibition by type I interferons in human breast cancer cells. Cancer Research 1998, 58:1914-1919.
40. Sheen-Chen S.-M., et al. Signal transducer and activator of transcription 1 in breast cancer: analysis with tissue microarray. Anticancer Research 2007, 27:2481-2486.
41. Uluer E.T., et al. Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway. Acta Histochemica 2012, 114:641-646.
42. Vafaizadeh V., Klemmt P.A., Groner B. STAT 5 assumes distinct functions in mammary gland development and mammary tumor formation. Frontiers in Bioscience 2012, 17:1232-1250.
43. Van Agthoven T., et al. Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines. International Journal of Cancer. Journal International du Cancer 2012, 131:1998-2007.
44. Widschwendter A., et al. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clinical Cancer Research 2002, 8:3065-3074.
45. Yamashita H., et al. STAT 5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocrine Related Cancer 2006, 13:885-893.
46. Yamashita H., et al. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Science 2009, 100:2028-2033.
47. Yau C., et al. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Research 2010, 12:R85.
48. Yeh Y.-T., et al. STAT 3 ser727 phosphorylation and its association with negative estrogen receptor status in breast infiltrating ductal carcinoma. International journal of cancer. Journal International du Cancer 2006, 118:2943-2947.
49. Zhang W.J., et al. IL-4-induced STAT 6 activities affect apoptosis and gene expression in breast cancer cells. Cytokine 2008, 42:39-47.